Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs
Executive Summary
Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product
You may also be interested in...
Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit
FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit
FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.